press release
HonorHealth Research Institute is the first of 50 sites worldwide to treat a patient in a new clinical study aimed at melanoma
New therapy uses modified immune-system T cells to target PRAME, a peptide commonly found in difficult-to-treat melanoma skin cancer tumors
